NasdaqGS - Delayed Quote USD
Relmada Therapeutics, Inc. (RLMD)
At close: 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-48,180.6160
-51,659.2060
-103,801.6170
-91,873.3950
-27,808.8010
Investing Cash Flow
35,674.2380
50,453.3320
19,733.6090
-54,118.0360
-34,447.6480
Financing Cash Flow
123.2840
-98.4630
45,020.4740
187,939.4730
28,473.3270
End Cash Position
2,086.2600
4,091.5680
5,395.9050
44,443.4390
2,495.3970
Interest Paid Supplemental Data
--
--
--
--
2.4150
Issuance of Capital Stock
246.7470
--
42,728.5990
185,311.4120
20,527.1580
Repayment of Debt
--
--
--
--
-110.2470
Free Cash Flow
-48,180.6160
-51,659.2060
-103,801.6170
-91,873.3950
-27,808.8010
12/31/2020 - 6/20/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
YMAB Y-mAbs Therapeutics, Inc.
14.85
+1.99%
APLT Applied Therapeutics, Inc.
8.72
-3.00%
TCRX TScan Therapeutics, Inc.
5.24
-0.57%
ALEC Alector, Inc.
4.7000
+1.95%
INZY Inozyme Pharma, Inc.
5.11
-3.22%
SYRE Spyre Therapeutics, Inc.
34.15
+5.30%
MRUS Merus N.V.
53.19
+3.08%
NAMS NewAmsterdam Pharma Company N.V.
18.92
-0.53%
ALRN Aileron Therapeutics, Inc.
3.6700
+2.80%
VTYX Ventyx Biosciences, Inc.
2.2500
-5.86%